denovologo.png

 

 

 

 

 

 

 

Denovo Biopharma Announces New Hires for Positions of Chief Medical Officer of Hematology and Senior Vice President, Regulatory Affairs and Quality Assurance

 

SAN DIEGO, February 21, 2019 -- Denovo Biopharma, a leader in precision medicine, today announced the hiring of two senior executives, reporting to the CEO: Lei Zhang, MD, as Chief Medical Officer, Hematology, and Bruce M. Wagman, as Senior Vice President, Regulatory Affairs and Quality Assurance.

Dr. Zhang, MD, has been appointed Chief Medical Officer, Hematology. Dr. Zhang has extensive clinical trial experience leading to global regulatory approvals of drugs in multiple indications in the US and Europe. Most recently, Dr. Zhang served as Executive Medical Director/Program Lead at Celgene Corporation, where she was the Program Lead for REVLIMID® and the biomarker-driven global Phase 3 Diffuse Large B Cell registration program. Prior to Celgene Dr. Zhang worked at Novartis Pharmaceuticals Corporation and Eli Lilly and Company. Dr. Zhang received her MD from Capital Medical University, Beijing, China, and earned a MS in Biochemistry from Medical College of Virginia, Richmond, VA.

Mr. Wagman has held positions of increasing managerial and technical responsibility at companies such as Prometheus Laboratories, Covance Inc., MDS-Pharma, Inc., Astra USA, Inc., and Bristol-Myers Squibb, Inc. He has been actively engaged in the healthcare industry for thirty-six years, including twenty-eight years as a Regulatory Affairs professional in the pharmaceutical industry and as a Captain in the United States Air Force Nurse Corps. Mr. Wagman received his Master of Business Administration degree from Drexel University and his Bachelor of Science degree in Nursing from Syracuse University.

 

About Denovo Biopharma

 

Denovo Biopharma is a clinical stage biopharmaceutical company that applies novel biomarker approaches to precision drug development to re-evaluate medicines that have failed in broad patient populations. The company applies its expertise to archived clinical samples to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. Denovo then designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo is enrolling patients in the U.S. and China with diffuse large B-cell lymphoma (DLBCL) in a Phase 3 clinical trial for its lead product candidate, DB102, which was in-licensed from Eli Lilly. The company has two additional late stage programs: DB103, for schizophrenia, and DB104, for depression. For additional information please visit www.denovobiopharma.com.

 

Contact:

 

Michael F. Haller, Chief Business Officer

Denovo Biopharma LLC

mhaller@denovobiopharma.com